HUTCHMED DRC

NASDAQ HCM

Data sourced from

and

Download Data

HUTCHMED DRC Gross Profit for the quarter ending December 31, 2023: None -14.18 M

HUTCHMED DRC Gross Profit is None -14.18 M for the quarter ending December 31, 2023, a 81.65% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

HUTCHMED DRC Gross Profit for the quarter ending December 31, 2022 was None -77.29 M, a -1,047.62% change year over year.
HUTCHMED DRC Gross Profit for the quarter ending December 31, 2021 was None 8.16 M, a -50.91% change year over year.
HUTCHMED DRC Gross Profit for the quarter ending December 31, 2020 was None 16.62 M, a 127.43% change year over year.
HUTCHMED DRC Gross Profit for the quarter ending December 31, 2019 was None -60.57 M, a -640.23% change year over year.

NASDAQ: HCM

HUTCHMED DRC

CEO	Mr. Chi Keung To ACGI, B.Sc., BSc, M.B.A., MBA
IPO Date	March 17, 2016
Location	Hong Kong
Headquarters	Cheung Kong Center, Central, Hong Kong
Employees	1,988
Sector	Healthcare
Industry	Drug manufacturers - specialty & generic

Description

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

Key trends